In the multivariable analysis , bevacizumab treatment ( hazard ratio -LSB- HR -RSB- , @ ; P = @ ) and age ( HR , @ ; P = @ ) were significantly associated with the risk of ATE ; whereas age ( HR , @ ; P = @ ) and VTE risk score ( HR , @ ; P = @ ) were significantly associated with the risk of VTE .